Chonluten is a short, synthetic peptide originally developed from natural peptides derived from bronchial mucosa. As with other cytogenetic peptides, Chonluten has been studied for its ability to influence gene expression, modulate inflammatory responses, and support tissue regeneration—specifically within the respiratory system and epithelial tissues.
While it is not approved for human use, Chonluten has been the subject of preclinical investigations, especially in Russia, focusing on pulmonary inflammation, immune modulation, and cellular differentiation.
1. Pulmonary and Bronchial Tissue Regulation
Preclinical studies show that Chonluten can influence the expression of genes related to lung epithelial repair and bronchial tissue integrity. In models of chronic obstructive pulmonary disease (COPD), Chonluten helped normalize bronchial epithelium and reduce structural damage following inflammation or oxidative injury[1].
These findings position Chonluten as a candidate for research exploring bronchial regeneration, asthma pathology, and post-infectious pulmonary remodeling.
2. Epigenetic Influence on Inflammation and Cellular Senescence
Like other short regulatory peptides, Chonluten appears to function at the epigenetic level—modulating gene expression related to cytokine release, immune signaling, and cellular turnover. Animal studies indicate that it can reduce levels of pro-inflammatory cytokines such as TNF-α and IL-6, while enhancing expression of protective factors like IL-10 and transforming growth factor beta (TGF-β)[2].
These immunomodulatory effects suggest Chonluten may be useful in research studying chronic inflammation, fibrosis, and epithelial-mesenchymal transition (EMT).
3. Mucosal Barrier and Respiratory Defense
One underexplored area is Chonluten’s potential in maintaining mucosal barrier function. Preliminary data suggests it may enhance local immune surveillance in respiratory epithelium and support goblet cell differentiation and cilia regeneration[3].
This may make it relevant to study in models of respiratory tract infections, airway remodeling, or immune-compromised pulmonary environments.
Potential Research Study Applications
Given its bioactivity and preclinical data, Chonluten could be valuable in the following study models:
- Chronic respiratory disease (e.g., COPD, asthma, chronic bronchitis)
- Post-viral lung repair (e.g., influenza or SARS-CoV-2 models)
- Lung fibrosis and epithelial regeneration
- Epigenetic modulation of inflammatory cytokines
- Mucosal immunity and microbiota interactions in the airways
- Preclinical toxicology of environmental/chemical lung exposure
- Aging-related decline in respiratory function
These applications highlight Chonluten as a multifaceted peptide with broad investigational value in respiratory, aging, and immune research.
For Research Use Only
At Battle Born Peptides, we offer high-purity Chonluten strictly for in vitro and preclinical use. Our peptides are not intended for human consumption or therapeutic application. They are supplied exclusively for qualified researchers pursuing evidence-based experimental studies.
References
- Khavinson, V.K., et al. (2009). Cytogenetic peptides and bronchial epithelial repair in rats with chronic airway inflammation. Bulletin of Experimental Biology and Medicine, 148(4), 455–460.
- Trofimova, S.V., et al. (2011). Immunomodulatory effects of the peptide Chonluten in models of airway inflammation. Advances in Gerontology, 24(3), 303–309.
- Malinin, V.V., et al. (2010). Peptide-induced restoration of ciliated epithelium and goblet cell homeostasis in bronchi. Pathophysiology of Respiratory Function, 17(2), 205–212.